Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 183

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 5
Chunk 183
---
. Accordingly, there can be no assurance that our plans can be effectively implemented and, therefore, that the conditions can be effectively mitigated.
 
Until such time, if ever, we expect to finance our operations through equity or debt financings, which may not be available to us on the timing needed or on terms that we deem to be favorable. To the extent that we raise additional capital through the sale of equity or debt securities, the ownership interest of our shareholders will be diluted. If we are unable to maintain sufficient financial resources, our business, financial condition and results of operations will be materially and adversely affected.
 
Cash Flows
 
The following table presents the major components of net cash flows used in or provided by (as applicable) operating, investing and financing activities for the periods presented. For a discussion of our net cash flows for the year ended December 31, 2022, please see “Item 5. Operating and Financial Review and Prospects— B. Liquidity and Capital Resources— Cash Flows” in our Annual Report on Form 20-F for the year ended December 31, 2023, which we filed with the SEC on March 28, 2024:

                                                                       2024                    2023                    2022          
-------------------------------------------------------------------------------------------------------------------------------------
(U.S. dollars, in thousands)                                                                                                         
Net cash used in operating activities                                $(19,700       )       $(21,577        )       $(23,678        )
Net cash provided by (used in) investing activities                         9,622                  (4,538   )              13,274    
Net cash provided by financing activities                                   4,656                  18,152                   9,343    
Exchange rate differences - cash and cash equivalents balances                (49   )                (245   )              (2,284   )
Decrease in cash and cash equivalents                                $(5,471        )       $(8,208         )       $(3,345         )
Cash Used in Operating Activities
 
             Cash used in operating activities for the year ended December 31, 2024 was approximately $19.7 million and primarily reflects our overall loss of approximately $18.1 million, as adjusted upwards to eliminate certain non-cash items that were taken into account in calculating, and that decreased, our overall loss, including approximately $6.5 million of non-cash financial income related to remeasurement of pre-funded warrants and warrants, approximately $0.7 million of non-cash net financing income and approximately $3